{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:05:30Z","timestamp":1779872730725,"version":"3.53.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.hrthm.2025.06.039","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:18:37Z","timestamp":1750965517000},"page":"1411-1422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ivabradine: Evolving role as an antiarrhythmic agent"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-6446","authenticated-orcid":false,"given":"Christopher M.","family":"Janson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2025.06.039_bib1","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The clinical use of ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10557-020-07124-4","article-title":"Ivabradine in cardiovascular disease management revisited: a review","volume":"35","author":"Chen","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hrthm.2025.06.039_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000073933","article-title":"A single intravenous dose of ivabradine, a (novel If inhibitor, lowers heart rate but does) not depress left ventricular function in patients with left ventricular dysfunction","volume":"100","author":"Manz","year":"2003","journal-title":"Cardiology"},{"key":"10.1016\/j.hrthm.2025.06.039_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/heartjnl-2012-302301","article-title":"Heart rate: surrogate or target in the management of heart failure?","volume":"99","author":"B\u00f6hm","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.hrthm.2025.06.039_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjmed.2014.09.016","article-title":"Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease","volume":"128","author":"B\u00f6hm","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.hrthm.2025.06.039_bib6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (Beautiful): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2025.06.039_bib7","first-page":"1988","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2025.06.039_bib8","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2025.06.039_bib9","first-page":"56","article-title":"Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients With Heart Failure","volume":"9","author":"FaLa","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.hrthm.2025.06.039_bib11","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jacc.2017.07.725","article-title":"Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure","volume":"70","author":"Bonnet","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15829\/1560-4071-2020-2-3757","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"25","author":"Knuuti","year":"2020","journal-title":"Russ J Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib13","first-page":"e506","article-title":"2015. ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines and the Heart Rhythm Society","volume":"133","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.06.039_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1540-8167.2010.01860.x","article-title":"Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine","volume":"22","author":"Bohora","year":"2011","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib15","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.hrthm.2021.03.020","article-title":"Effect of ivabradine on cardiac arrhythmias: antiarrhythmic or proarrhythmic?","volume":"18","author":"Marciszek","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053132","article-title":"Identification of the molecular site of ivabradine binding to HCN4 channels","volume":"8","author":"Bucchi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.hrthm.2025.06.039_bib17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.hrthm.2020.07.031","article-title":"The rationale for repurposing funny current inhibition for management of ventricular arrhythmia","volume":"18","author":"Chakraborty","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2014.06.1155","article-title":"The symptom complex of familial sinus node dysfunction and myocardial noncompaction is associated with mutations in the HCN4 channel","volume":"64","author":"Schweizer","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00395-009-0031-5","article-title":"Transcription profiling of HCN-channel isotypes throughout mouse cardiac development","volume":"104","author":"Schweizer","year":"2009","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib20","series-title":"Modern Pacemakers - Present and Future","first-page":"595","article-title":"The funny current in cardiac non-pacemaker cells: functional role and pharmacological modulation","author":"Sartiani","year":"2011"},{"key":"10.1016\/j.hrthm.2025.06.039_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000150","article-title":"Increased expression of HCN channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts","volume":"2","author":"Kuwabara","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2025.06.039_bib22","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/pace.13480","article-title":"Beneficial effects of ivabradine in atrial or ventricular arrhythmias","volume":"41","author":"Mert","year":"2018","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/jcp.24507","article-title":"Ivabradine protects against ventricular arrhythmias in acute myocardial infarction in the rat","volume":"229","author":"Mackiewicz","year":"2014","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib24","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1476-5381.2011.01627.x","article-title":"Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression","volume":"165","author":"Suffredini","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2305135120","article-title":"A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family","volume":"120","author":"C\u00e1mara-Checa","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hrthm.2025.06.039_bib26","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jacc.2014.05.045","article-title":"HCN4 mutations in multiple families with bradycardia and left ventricular noncompaction cardiomyopathy","volume":"64","author":"Milano","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1540-8159.2009.02563.x","article-title":"The contribution of HCN4 to normal sinus node function in humans and animal models","volume":"33","author":"Nof","year":"2010","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib28","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.hrthm.2014.08.007","article-title":"If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation","volume":"11","author":"Verrier","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00126839-200304020-00001","article-title":"Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology","volume":"4","author":"Camm","year":"2003","journal-title":"Drugs R D"},{"key":"10.1016\/j.hrthm.2025.06.039_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.001813","article-title":"hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine","volume":"4","author":"Melgari","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2025.06.039_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejphar.2011.07.025","article-title":"Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions","volume":"668","author":"Koncz","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijcard.2017.02.055","article-title":"Effective suppression of atrial fibrillation by ivabradine: novel target for an established drug?","volume":"236","author":"Frommeyer","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.hrthm.2023.02.012","article-title":"Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial","volume":"20","author":"Fontenla","year":"2023","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib34","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacep.2023.05.019","article-title":"Serum ivabradine Associates with heart rate Reduction but enteral Exposure Is Unpredictable in Post surgical JET","volume":"9","author":"Sylva","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10928-015-9451-z","article-title":"Model-based approaches for ivabradine development in paediatric population, part I: Study preparation assessment","volume":"43","author":"Peigne","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.hrthm.2025.06.039_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10928-015-9452-y","article-title":"Model-based approaches for ivabradine development in paediatric population, part II: PK and PK\/PD assessment","volume":"43","author":"Peign\u00e9","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.hrthm.2025.06.039_bib37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s13256-022-03554-w","article-title":"Ivabradine toxicity: a case report","volume":"16","author":"Singh","year":"2022","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.hrthm.2025.06.039_bib38","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.hrthm.2016.03.015","article-title":"Adjunctive ivabradine in combination with amiodarone: A novel therapy for pediatric congenital junctional ectopic tachycardia","volume":"13","author":"Dieks","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib39","first-page":"573","article-title":"Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: a preliminary report","volume":"23","author":"N\u00fa\u00f1ez","year":"2016","journal-title":"Cardiol J"},{"key":"10.1016\/j.hrthm.2025.06.039_bib40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacep.2021.01.020","article-title":"Ivabradine versus amiodarone in the management of postoperative junctional ectopic tachycardia: a randomized, open-label, noninferiority study","volume":"7","author":"Arvind","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib41","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.hrthm.2025.06.039_bib42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/clc.22578","article-title":"The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients","volume":"39","author":"Tanbo\u011fa","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12012-014-9274-y","article-title":"Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction","volume":"15","author":"Cocco","year":"2015","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib44","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1074248416672008","article-title":"Ivabradine: do the benefits outweigh the risks?","volume":"22","author":"Alshammari","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.06.039_bib45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.14740\/cr1392","article-title":"Ivabradine overdose in a newborn: precautions of dispensing in infants","volume":"13","author":"Doctor","year":"2022","journal-title":"Cardiol Res"},{"key":"10.1016\/j.hrthm.2025.06.039_bib46","first-page":"183","article-title":"Ivabradine toxicity: a case report and review","volume":"6","author":"Osei","year":"2020","journal-title":"Heart Rhythm Case Rep"},{"key":"10.1016\/j.hrthm.2025.06.039_bib47","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/pace.12163","article-title":"Postoperative junctional ectopic tachycardia: risk factors for occurrence in the modern surgical era","volume":"36","author":"Moak","year":"2013","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib49","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/joa3.13155","article-title":"Use of ivabradine in children with junctional ectopic tachycardia after pediatric cardiac surgery; two-centre experience","volume":"40","author":"Kamali","year":"2024","journal-title":"J Arrhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib82","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007387","article-title":"Clinical and electrophysiological correlates of incessant ivabradine-sensitive atrial tachycardia","volume":"12","author":"Banavalikar","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib83","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.hrthm.2023.10.013","article-title":"Early experience with ivabradine for focal atrial tachycardia in pediatric patients with congenital heart disease","volume":"21","author":"Tolani","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib71","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2012.06.031","article-title":"Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: A prospective, randomized, placebo-controlled, double-blind, crossover evaluation","volume":"60","author":"Cappato","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib74","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2459\/JCM.0000000000001203","article-title":"Ivabradine versus bisoprolol in the treatment of inappropriate sinus tachycardia: a long-term follow-up study","volume":"22","author":"Martino","year":"2021","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.hrthm.2025.06.039_bib48","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ihj.2017.09.007","article-title":"Ivabradine for junctional ectopic tachycardia in post congenital heart surgery","volume":"69","author":"Kumar","year":"2017","journal-title":"Indian Heart J"},{"key":"10.1016\/j.hrthm.2025.06.039_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/anec.13064","article-title":"Ivabradine in the treatment of non-paroxysmal junctional tachycardia with interference atrioventricular dissociation: a case report","volume":"28","author":"Ying","year":"2023","journal-title":"Ann Noninvas Electrocardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2023-258901","article-title":"Successful treatment with ivabradine for haemodynamically unstable junctional ectopic tachycardia occurring early after ST-elevation myocardial infarction","volume":"17","author":"Numao","year":"2024","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.hrthm.2025.06.039_bib52","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00246-019-02149-5","article-title":"Ivabradine in post-operative junctional ectopic tachycardia (JET): breaking new ground","volume":"40","author":"Krishna","year":"2019","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib53","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/2150135119876600","article-title":"Ivabradine as an adjunct for refractory junctional ectopic tachycardia following pediatric cardiac surgery: a preliminary study","volume":"10","author":"Kumar","year":"2019","journal-title":"World J Pediatr Congenit Hear Surg"},{"key":"10.1016\/j.hrthm.2025.06.039_bib54","doi-asserted-by":"crossref","first-page":"160","DOI":"10.15406\/jpnc.2019.09.00399","article-title":"New therapeutic option for junctional ectopic tachycardia in infants following congenital heart surgery: ivabradine, a case report","volume":"9","author":"Touma Boulos","year":"2019","journal-title":"J Pediatr Neonatal Care"},{"key":"10.1016\/j.hrthm.2025.06.039_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4236\/wjcs.2019.98009","article-title":"Ivabradine\u2014the final crusader for postoperative junctional ectopic tachycardia, a case report with literature review","volume":"9","author":"Sahu","year":"2019","journal-title":"World J Cardiovasc Surg"},{"key":"10.1016\/j.hrthm.2025.06.039_bib56","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1053\/j.jvca.2020.02.047","article-title":"Use of ivabradine in the treatment of tachyarrhythmias after surgery for congenital heart diseases","volume":"34","author":"Khan","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.hrthm.2025.06.039_bib57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12055-020-01056-2","article-title":"Use of ivabradine for treatment of junctional ectopic tachycardia in post congenital heart surgery","volume":"37","author":"Sharma","year":"2021","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hrthm.2025.06.039_bib58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anpedi.2020.09.002","article-title":"Use of ivabradine in pediatric post-operative junctional ectopic tachycardia","volume":"95","author":"L\u00f3pez Fern\u00e1ndez","year":"2021","journal-title":"Anales de Pediatria"},{"key":"10.1016\/j.hrthm.2025.06.039_bib59","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.19102\/icrm.2023.14075","article-title":"Combination therapy of ivabradine with procainamide for the management of pediatric postoperative junctional ectopic tachycardia","volume":"14","author":"Dasgupta","year":"2023","journal-title":"J Innov Card Rhythm Manag"},{"key":"10.1016\/j.hrthm.2025.06.039_bib60","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jacep.2021.03.015","article-title":"Ivabradine for postoperative JET: clear for take-off?","volume":"7","author":"Janson","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib61","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jce.12081","article-title":"Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia","volume":"24","author":"Al-Ghamdi","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib62","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/pace.13402","article-title":"Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: case studies","volume":"41","author":"Ergul","year":"2018","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib63","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/apc.APC_25_18","article-title":"Ivabradine for congenital junctional ectopic tachycardia in siblings","volume":"11","author":"Kothari","year":"2018","journal-title":"Ann Pediatr Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib64","first-page":"414","article-title":"Ivabradine monotherapy for the treatment of congenital junctional ectopic tachycardia in a premature neonate","volume":"26","author":"Asfour","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.06.039_bib65","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/pediatric13040074","article-title":"Ivabradine\u2013flecainide as breakthrough drug combination for congenital junctional ectopic tachycardia: A case report and literature review","volume":"13","author":"Di Marco","year":"2021","journal-title":"Pediatr Rep"},{"key":"10.1016\/j.hrthm.2025.06.039_bib66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/apc.apc_264_20","article-title":"Ivabradine monotherapy in congenital junctional ectopic tachycardia","volume":"15","author":"Devaprasath","year":"2022","journal-title":"Ann Pediatr Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1047951121005187","article-title":"Congenital junctional ectopic tachycardia in the paediatric emergency department","volume":"32","author":"Memon","year":"2022","journal-title":"Cardiol Young"},{"key":"10.1016\/j.hrthm.2025.06.039_bib68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1017\/S1047951123003669","article-title":"Ivabradine for congenital ectopic tachycardia in newborn","volume":"34","author":"Pamukcu","year":"2024","journal-title":"Cardiol Young"},{"key":"10.1016\/j.hrthm.2025.06.039_bib69","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.hrcr.2019.03.007","article-title":"Ivabradine for treatment of tachyarrhythmias in children and young adults","volume":"5","author":"Janson","year":"2019","journal-title":"HeartRhythm Case Rep"},{"key":"10.1016\/j.hrthm.2025.06.039_bib70","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/pace.14812","article-title":"Ivabradine as a treatment option for junctional ectopic tachycardia in an adult female","volume":"47","author":"Baldi","year":"2024","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib72","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.hrthm.2023.11.009","article-title":"Ivabradine in the management of elevated resting heart rate associated with mediastinal radiation therapy","volume":"21","author":"Itzhaki Ben Zadok","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/europace\/euq390","article-title":"Single centre experience of ivabradine in postural orthostatic tachycardia syndrome","volume":"13","author":"McDonald","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2025.06.039_bib75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/europace\/eus204","article-title":"Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy","volume":"15","author":"Ptaszynski","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2025.06.039_bib76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10840-015-0066-5","article-title":"Treatment of inappropriate sinus tachycardia with ivabradine","volume":"46","author":"Annamaria","year":"2016","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib77","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/jce.14942","article-title":"Efficacy of medical and ablation therapy for inappropriate sinus tachycardia: a single-center experience","volume":"32","author":"Shabtaie","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib78","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/jce.14940","article-title":"Treatment of inappropriate sinus tachycardia: still a long way to go","volume":"32","author":"Cappato","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib79","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/pace.12118","article-title":"Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients","volume":"36","author":"Benezet-Mazuecos","year":"2013","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib80","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.hrthm.2010.05.034","article-title":"Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia","volume":"7","author":"Cal","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib81","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cardiores.2006.07.026","article-title":"Extended atrial conduction system characterised by the expression of the HCN4 channel and connexin45","volume":"72","author":"Yamamoto","year":"2006","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2025.06.039_bib84","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s00431-023-04891-8","article-title":"Ivabradine monotherapy in pediatric patients with focal atrial tachycardia: a single-center study","volume":"182","author":"Xu","year":"2023","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.hrthm.2025.06.039_bib110","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1540-8167.2007.00955.x","article-title":"The heart rate-lowering agent ivabradine inhibits the pacemaker current If in human atrial myocytes","volume":"18","author":"Chemaly","year":"2007","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib85","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1017\/S1047951120001195","article-title":"Ivabradine as a stabilising anti-arrhythmic agent for multifocal atrial tachycardia","volume":"30","author":"Cohen","year":"2020","journal-title":"Cardiol Young"},{"key":"10.1016\/j.hrthm.2025.06.039_bib86","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.123.012022","article-title":"HRAS -mutant cardiomyocyte model of multifocal atrial tachycardia","volume":"17","author":"Rodr\u00edguez","year":"2024","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib87","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1161\/CIRCULATIONAHA.116.018011","article-title":"Sinus node and atrial arrhythmias","volume":"133","author":"John","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.06.039_bib88","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1540-8167.2011.02173.x","article-title":"Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis","volume":"23","author":"Chen","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib89","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijcard.2016.09.044","article-title":"Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation","volume":"224","author":"Wongcharoen","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib90","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.recesp.2017.03.005","article-title":"Ivabradina como alternativa a la ablaci\u00f3n del n\u00f3dulo AV para un paciente con fibrilaci\u00f3n auricular permanente","volume":"70","author":"Fontenla","year":"2017","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib91","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/1753944716669658","article-title":"Emerging role of ivabradine for rate control in atrial fibrillation","volume":"10","author":"Turley","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.hrthm.2025.06.039_bib92","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10840-022-01344-4","article-title":"Ventricular rate control with ivabradine in patients with permanent atrial fibrillation","volume":"65","author":"Chan","year":"2022","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib93","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.CIR.94.7.1674","article-title":"Occurrence and properties of the hyperpolarization-activated current I(f) in ventricular myocytes from normotensive and hypertensive rats during aging","volume":"94","author":"Cerbai","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.06.039_bib94","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.yjmcc.2008.04.013","article-title":"Molecular basis of funny current (If) in normal and failing human heart","volume":"45","author":"Stillitano","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib95","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bcpt.12829","article-title":"Ivabradine reduces digitalis-induced ventricular arrhythmias","volume":"121","author":"Frommeyer","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib96","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/1440-1681.12790","article-title":"Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome","volume":"44","author":"Frommeyer","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib97","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1540-8167.2011.02285.x","article-title":"Differential effects of ivabradine and ryanodine on pacemaker activity in canine sinus node and Purkinje fibers","volume":"23","author":"Sosunov","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib98","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.hrthm.2007.09.028","article-title":"HCN212-channel biological pacemakers manifesting ventricular tachyarrhythmias are responsive to treatment with If blockade","volume":"5","author":"Plotnikov","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.06.039_bib99","first-page":"545","article-title":"Multifocal ectopic premature Purkinje-related complexes syndrome in children","volume":"9","author":"Young","year":"2023","journal-title":"Hear Case Rep"},{"key":"10.1016\/j.hrthm.2025.06.039_bib100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jelectrocard.2021.12.010","article-title":"The use of ivabradine in a patient with idiopathic ventricular arrhythmia originating from the left ventricular summit","volume":"71","author":"\u00c7inier","year":"2022","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib101","first-page":"36","article-title":"Significant suppression of premature ventricular ectopics with ivabradine in dilated cardiomyopathy","volume":"26","author":"Mughal","year":"2019","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib102","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pace.13913","article-title":"Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy","volume":"43","author":"Kohli","year":"2020","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib103","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/pace.13446","article-title":"Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"41","author":"Vaksmann","year":"2018","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207100","article-title":"Arrhythmia initiation in catecholaminergic polymorphic ventricular tachycardia type 1 depends on both heart rate and sympathetic stimulation","volume":"13","author":"Danielsen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.hrthm.2025.06.039_bib105","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/jce.14043","article-title":"Chronotropic incompetence as a risk predictor in children and young adults with catecholaminergic polymorphic ventricular tachycardia","volume":"30","author":"Franciosi","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib106","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fphar.2019.01566","article-title":"The hyperpolarization-activated cyclic-nucleotide-gated channel blocker ivabradine does not prevent arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"10","author":"Bueno-Levy","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hrthm.2025.06.039_bib107","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1536\/ihj.24-323","article-title":"Efficacy of ivabradine in preventing inappropriate shock due to sinus tachycardia in a patient with cardiac sarcoidosis","volume":"65","author":"Masuda","year":"2024","journal-title":"Int Heart J"},{"key":"10.1016\/j.hrthm.2025.06.039_bib108","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcct.2015.04.005","article-title":"Intravenous ivabradine for control of heart rate during coronary CT angiography: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Cademartiri","year":"2015","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.hrthm.2025.06.039_bib109","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13054-018-2124-8","article-title":"Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial","volume":"22","author":"Nguyen","year":"2018","journal-title":"Crit Care"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125026189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125026189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T08:32:52Z","timestamp":1779870772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527125026189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1547527125026189"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.06.039","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivabradine: Evolving role as an antiarrhythmic agent","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.06.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}